Financial Statement

Fiscal Year Ends	:	December
( in million Rupiah except Par Value, Per Share Data and Ratios )
Statement Date	:	2024-03-31
Balance Sheet
Cash & Cash Equivalents	:	124,368
Curr. Assets	:	1,838,262
Fixed Assets	:	2,886,646
Total Assets	:	4,724,908
Curr. Liabilities	:	2,287,328
Long Term Debt	:	850,759
Minority Interest	:	0
Total Liabilities	:	3,138,088
Paid-Up Capital	:	1,429
Total Equity	:	1,586,821
Income Statement
Total Sales	:	1,103,664
Gross Profit	:	462,219
Operating Profit	:	20,715
Net Income	:	19,039
Cash Flow Statement
Cash From Operating Act	:	-42,557
Cash From Investing Act	:	-26,670
Cash From Financing Act	:	23,842
Per Share Data (in IDR)
EPS	:	13.33
Book Value	:	1,110.77
Financial Ratios
Der	:	1.98
Roa	:	0.07
Roe	:	0.05
Npm	:	0.02
Opm	:	0.02
Growth Year to Year
Sales (%)	:	100.00%
Net Income (%)	:	100.00%
Total Assets (%) (%)	:	100.00%
Total Liabilities (%)	:	100.00%

1	ABL Bio Umumkan Kerja sama Lisensi Platform Pengantar Molekul Grabody-B bersama GSK, Kembangkan Obat Neurodegeneratif

2	Perma-Pipe International Holdings, Inc. umumkan pemberian proyek baru di Timur Tengah dan Afrika Utara serta Amerika

3	IHSG Jumat dibuka melemah 58,45 poin

4	Valmont Telah Hadir di The Ritz-Carlton Spa, Bali

5	Acara "Dialogue in the New Era: China-Vietnam Exchange for Young Media Professionals" Digelar dengan Sukses

ABL Bio Umumkan Kerja sama Lisensi Platform Pengantar Molekul Grabody-B bersama GSK, Kembangkan Obat Neurodegeneratif